These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 16360430)

  • 1. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Adamovich E
    Urology; 2005 Dec; 66(6):1150-4. PubMed ID: 16360430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
    Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Butler EG; Allen ZA; Adamovich E
    Urol Nurs; 2006 Aug; 26(4):298-303. PubMed ID: 16939047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Urology; 2005 Nov; 66(5):1048-53. PubMed ID: 16286122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Deger S; Boehmer D; Roigas J; Schink T; Wernecke KD; Wiegel T; Hinkelbein W; Budach V; Loening SA
    Eur Urol; 2005 Apr; 47(4):441-8. PubMed ID: 15774239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
    Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L
    BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer.
    Soto DE; Daignault S; Sandler HM; Ray ME
    Urology; 2009 Jan; 73(1):158-62. PubMed ID: 18722651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer.
    Merrick GS; Galbreath RW; Butler WM; Waller KE; Allen ZA; Lief J; Adamovich E
    Cancer; 2007 Jul; 110(2):289-96. PubMed ID: 17549691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation.
    Zelefsky MJ; Kuban DA; Levy LB; Potters L; Beyer DC; Blasko JC; Moran BJ; Ciezki JP; Zietman AL; Pisansky TM; Elshaikh M; Horwitz EM
    Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):327-33. PubMed ID: 17084558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimized prostate brachytherapy minimizes the prognostic impact of percent of biopsy cores involved with adenocarcinoma.
    Nurani R; Wallner K; Merrick G; Virgin J; Orio P; True LD
    J Urol; 2007 Nov; 178(5):1968-73; discussion 1973. PubMed ID: 17868717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
    Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
    Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor control outcomes of patients treated with trimodality therapy for locally advanced prostate cancer.
    Copp H; Bissonette EA; Theodorescu D
    Urology; 2005 Jun; 65(6):1146-51. PubMed ID: 15922433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.